Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?

  • Jae Hyon Park (Department of Radiology, Yonsei University College of Medicine) ;
  • Yong Eun Chung (Department of Radiology, Yonsei University College of Medicine) ;
  • Nieun Seo (Department of Radiology, Yonsei University College of Medicine) ;
  • Jin-Young Choi (Department of Radiology, Yonsei University College of Medicine) ;
  • Mi-Suk Park (Department of Radiology, Yonsei University College of Medicine) ;
  • Myeong-Jin Kim (Department of Radiology, Yonsei University College of Medicine)
  • Received : 2020.11.17
  • Accepted : 2021.04.07
  • Published : 2021.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Based on the Liver Imaging Reporting and Data System version 2018 (LI-RADS, v2018), this study aimed to analyze LR-5 diagnostic performance for hepatocellular carcinoma (HCC) when threshold growth as a major feature is replaced by a more HCC-specific ancillary feature, as well as the frequency of threshold growth in HCC and non-HCC malignancies and its association with tumor size. Materials and Methods: This retrospective study included treatment-naive patients who underwent gadoxetate disodium-enhanced MRIs for focal hepatic lesions and surgery between January 2009 and December 2016. The frequency of major and ancillary features was evaluated for HCC and non-HCC malignancies, and the LR-category was assessed. Ancillary features that were significantly more prevalent in HCC were then used to either replace threshold growth or were added as additional major features, and the diagnostic performance of the readjusted LR category was compared to the LI-RADS v2018. Results: A total of 1013 observations were analyzed. Unlike arterial phase hyperenhancement, washout, or enhancing capsule which were more prevalent in HCCs than in non-HCC malignancies (521/616 vs. 18/58, 489/616 vs. 19/58, and 181/616 vs. 5/58, respectively; p < 0.001), threshold growth was more prevalent in non-HCC malignancies than in HCCs (11/23 vs. 17/119; p < 0.001). The mean size of non-HCC malignancies showing threshold growth was significantly smaller than that of non-HCC malignancies without threshold growth (22.2 mm vs. 42.9 mm, p = 0.040). Similar results were found for HCCs; however, the difference was not significant (26.8 mm vs. 33.1 mm, p = 0.184). Additionally, Fat-in-nodule was more frequent in HCCs than in non-HCC malignancies (99/616 vs. 2/58, p = 0.010). When threshold growth and fat-in-nodule were considered as ancillary and major features, respectively, LR-5 sensitivity (73.2% vs. 73.9%, p = 0.289) and specificity (98.2% vs. 98.5%, p > 0.999) were comparable to the LI-RADS v2018. Conclusion: Threshold growth is not a significant diagnostic indicator of HCC and is more common in non-HCC malignancies. The diagnostic performance of LR-5 was comparable when threshold growth was recategorized as an ancillary feature and replaced by a more HCC-specific ancillary feature.

Keywords

Acknowledgement

Yong Eun Chung received faculty research grant of Yonsei University College of Medicine (No. 6-2019-0118).

References

  1. Kim YY, Kim MJ, Kim EH, Roh YH, An C. Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis: performance of LI-RADS version 2018. Radiology 2019;291:72-80  https://doi.org/10.1148/radiol.2019181995
  2. Kim YY, Choi JY, Sirlin CB, An C, Kim MJ. Pitfalls and problems to be solved in the diagnostic CT/MRI liver imaging reporting and data system (LI-RADS). Eur Radiol 2019;29:1124-1132  https://doi.org/10.1007/s00330-018-5641-6
  3. Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 2019;6:49-69  https://doi.org/10.2147/JHC.S186239
  4. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-380  https://doi.org/10.1002/hep.29086
  5. Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 2002;12:753-764  https://doi.org/10.1007/s00330-001-1142-z
  6. Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker. Radiology 2013;267:776-786  https://doi.org/10.1148/radiol.13120775
  7. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50  https://doi.org/10.1148/radiol.14132362
  8. Matsui O, Kobayashi S, Sanada J, Kouda W, Ryu Y, Kozaka K, et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 2011;36:264-272  https://doi.org/10.1007/s00261-011-9685-1
  9. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104 
  10. Kim TK, Lee KH, Jang HJ, Haider MA, Jacks LM, Menezes RJ, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 2011;259:730-738  https://doi.org/10.1148/radiol.11101549
  11. Ishigami K, Yoshimitsu K, Nishihara Y, Irie H, Asayama Y, Tajima T, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 2009;250:435-443  https://doi.org/10.1148/radiol.2501071702
  12. Lim JH, Choi D, Park CK, Lee WJ, Lim HK. Encapsulated hepatocellular carcinoma: CT-pathologic correlations. Eur Radiol 2006;16:2326-2333  https://doi.org/10.1007/s00330-006-0203-8
  13. Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma. Gut Liver 2019;13:227-299  https://doi.org/10.5009/gnl19024
  14. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-370  https://doi.org/10.1007/s12072-017-9799-9
  15. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-750  https://doi.org/10.1002/hep.29913
  16. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236  https://doi.org/10.1016/j.jhep.2018.03.019
  17. Rosenkrantz AB, Campbell N, Wehrli N, Triolo MJ, Kim S. New OPTN/UNOS classification system for nodules in cirrhotic livers detected with MR imaging: effect on hepatocellular carcinoma detection and transplantation allocation. Radiology 2015;274:426-433  https://doi.org/10.1148/radiol.14140069
  18. Kim JK, Kim HD, Jun MJ, Yun SC, Shim JH, Lee HC, et al. Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma. Dig Dis Sci 2017;62:2923-2931  https://doi.org/10.1007/s10620-017-4708-6
  19. An C, Choi YA, Choi D, Paik YH, Ahn SH, Kim MJ, et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol 2015;21:279-286  https://doi.org/10.3350/cmh.2015.21.3.279
  20. Shingaki N, Tamai H, Mori Y, Moribata K, Enomoto S, Deguchi H, et al. Serological and histological indices of hepatocellular carcinoma and tumor volume doubling time. Mol Clin Oncol 2013;1:977-981  https://doi.org/10.3892/mco.2013.186
  21. De Rose AM, Cucchetti A, Clemente G, Ardito F, Giovannini I, Ercolani G, et al. Prognostic significance of tumor doubling time in mass-forming type cholangiocarcinoma. J Gastrointest Surg 2013;17:739-747  https://doi.org/10.1007/s11605-012-2129-6
  22. Chernyak V, Kobi M, Flusberg M, Fruitman KC, Sirlin CB. Effect of threshold growth as a major feature on LI-RADS categorization. Abdom Radiol (NY) 2017;42:2089-2100  https://doi.org/10.1007/s00261-017-1105-8
  23. Park JH, Chung YE, Seo N, Choi JY, Park MS, Kim MJ. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: diagnostic performance of category-adjusted LR-5 using modified criteria. PLoS One 2020;15:e0242344 
  24. Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 2020;26:340-351  https://doi.org/10.3350/cmh.2020.0004
  25. American College of Radiology. CT/MRI LI-RADS® v2018. Acr.org Web site. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018. Accessed November 6, 2020 
  26. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503  https://doi.org/10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
  27. Lee S, Kim MJ, Kim SS, Shin H, Kim DY, Choi JY, et al. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Hepatol Int 2020;14:70-79  https://doi.org/10.1007/s12072-019-10002-3
  28. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-1417  https://doi.org/10.1097/00000478-199512000-00007
  29. Cerny M, Chernyak V, Olivie D, Billiard JS, Murphy-Lavallee J, Kielar AZ, et al. LI-RADS version 2018 ancillary features at MRI. Radiographics 2018;38:1973-2001  https://doi.org/10.1148/rg.2018180052
  30. Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol 2015;16:449-464  https://doi.org/10.3348/kjr.2015.16.3.449
  31. Cucchetti A, Vivarelli M, Piscaglia F, Nardo B, Montalti R, Grazi GL, et al. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005;43:310-316  https://doi.org/10.1016/j.jhep.2005.03.014
  32. Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Saisho H. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology 1998;45 Suppl 3:1214-1220 
  33. An C, Rakhmonova G, Choi JY, Kim MJ. Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm. Clin Mol Hepatol 2016;22:296-307  https://doi.org/10.3350/cmh.2016.0028
  34. Cerny M, Bergeron C, Billiard JS, Murphy-Lavallee J, Olivie D, Berube J, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology 2018;288:118-128  https://doi.org/10.1148/radiol.2018171678
  35. Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003;39:208-214 https://doi.org/10.1016/S0168-8278(03)00190-9